1032 related articles for article (PubMed ID: 34326167)
21. Single-cell RNA sequencing reveals compartmental remodeling of tumor-infiltrating immune cells induced by anti-CD47 targeting in pancreatic cancer.
Pan Y; Lu F; Fei Q; Yu X; Xiong P; Yu X; Dang Y; Hou Z; Lin W; Lin X; Zhang Z; Pan M; Huang H
J Hematol Oncol; 2019 Nov; 12(1):124. PubMed ID: 31771616
[TBL] [Abstract][Full Text] [Related]
22. Sonodynamic therapy complements PD-L1 immune checkpoint inhibition in a murine model of pancreatic cancer.
Nesbitt H; Logan K; Thomas K; Callan B; Gao J; McKaig T; Taylor M; Love M; Stride E; McHale AP; Callan JF
Cancer Lett; 2021 Oct; 517():88-95. PubMed ID: 34119606
[TBL] [Abstract][Full Text] [Related]
23. N
Liu Z; Wang T; She Y; Wu K; Gu S; Li L; Dong C; Chen C; Zhou Y
Mol Cancer; 2021 Aug; 20(1):105. PubMed ID: 34416901
[TBL] [Abstract][Full Text] [Related]
24. Long noncoding RNA Regulating ImMune Escape regulates mixed lineage leukaemia protein-1-H3K4me3-mediated immune escape in oesophageal squamous cell carcinoma.
Liu J; Zhou WY; Luo XJ; Chen YX; Wong CW; Liu ZX; Bo Zheng J; Yu Mo H; Chen JQ; Li JJ; Zhong M; Xu YH; Zhang QH; Pu HY; Wu QN; Jin Y; Wang ZX; Xu RH; Luo HY
Clin Transl Med; 2023 Sep; 13(9):e1410. PubMed ID: 37712124
[TBL] [Abstract][Full Text] [Related]
25. The prognostic impact of programmed cell death ligand 1 and human leukocyte antigen class I in pancreatic cancer.
Imai D; Yoshizumi T; Okano S; Uchiyama H; Ikegami T; Harimoto N; Itoh S; Soejima Y; Aishima S; Oda Y; Maehara Y
Cancer Med; 2017 Jul; 6(7):1614-1626. PubMed ID: 28602029
[TBL] [Abstract][Full Text] [Related]
26. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
27. Chemokine C-C motif ligand 21 synergized with programmed death-ligand 1 blockade restrains tumor growth.
Chen Q; Yin H; Pu N; Zhang J; Zhao G; Lou W; Wu W
Cancer Sci; 2021 Nov; 112(11):4457-4469. PubMed ID: 34402138
[TBL] [Abstract][Full Text] [Related]
28. Hollow Cu2MoS4 nanoparticles loaded with immune checkpoint inhibitors reshape the tumor microenvironment to enhance immunotherapy for pancreatic cancer.
Yao Z; Qi C; Zhang F; Yao H; Wang C; Cao X; Zhao C; Wang Z; Qi M; Yao C; Wang X; Xia H
Acta Biomater; 2024 Jan; 173():365-377. PubMed ID: 37890815
[TBL] [Abstract][Full Text] [Related]
29. An osteopontin/CD44 immune checkpoint controls CD8+ T cell activation and tumor immune evasion.
Klement JD; Paschall AV; Redd PS; Ibrahim ML; Lu C; Yang D; Celis E; Abrams SI; Ozato K; Liu K
J Clin Invest; 2018 Dec; 128(12):5549-5560. PubMed ID: 30395540
[TBL] [Abstract][Full Text] [Related]
30. Aldehyde Dehydrogenase 2 Mediates Alcohol-Induced Colorectal Cancer Immune Escape through Stabilizing PD-L1 Expression.
Zhang H; Xia Y; Wang F; Luo M; Yang K; Liang S; An S; Wu S; Yang C; Chen D; Xu M; Cai M; To KKW; Fu L
Adv Sci (Weinh); 2021 May; 8(10):2003404. PubMed ID: 34026438
[TBL] [Abstract][Full Text] [Related]
31. Combinational blockade of MET and PD-L1 improves pancreatic cancer immunotherapeutic efficacy.
Li E; Huang X; Zhang G; Liang T
J Exp Clin Cancer Res; 2021 Sep; 40(1):279. PubMed ID: 34479614
[TBL] [Abstract][Full Text] [Related]
32. MMP-9-cleaved osteopontin isoform mediates tumor immune escape by inducing expansion of myeloid-derived suppressor cells.
Shao L; Zhang B; Wang L; Wu L; Kan Q; Fan K
Biochem Biophys Res Commun; 2017 Dec; 493(4):1478-1484. PubMed ID: 28986261
[TBL] [Abstract][Full Text] [Related]
33. Overexpressed histone acetyltransferase 1 regulates cancer immunity by increasing programmed death-ligand 1 expression in pancreatic cancer.
Fan P; Zhao J; Meng Z; Wu H; Wang B; Wu H; Jin X
J Exp Clin Cancer Res; 2019 Feb; 38(1):47. PubMed ID: 30709380
[TBL] [Abstract][Full Text] [Related]
34. Entinostat Converts Immune-Resistant Breast and Pancreatic Cancers into Checkpoint-Responsive Tumors by Reprogramming Tumor-Infiltrating MDSCs.
Christmas BJ; Rafie CI; Hopkins AC; Scott BA; Ma HS; Cruz KA; Woolman S; Armstrong TD; Connolly RM; Azad NA; Jaffee EM; Roussos Torres ET
Cancer Immunol Res; 2018 Dec; 6(12):1561-1577. PubMed ID: 30341213
[TBL] [Abstract][Full Text] [Related]
35. Myeloid cells are required for PD-1/PD-L1 checkpoint activation and the establishment of an immunosuppressive environment in pancreatic cancer.
Zhang Y; Velez-Delgado A; Mathew E; Li D; Mendez FM; Flannagan K; Rhim AD; Simeone DM; Beatty GL; Pasca di Magliano M
Gut; 2017 Jan; 66(1):124-136. PubMed ID: 27402485
[TBL] [Abstract][Full Text] [Related]
36. Combination of PD-1 Inhibitor and OX40 Agonist Induces Tumor Rejection and Immune Memory in Mouse Models of Pancreatic Cancer.
Ma Y; Li J; Wang H; Chiu Y; Kingsley CV; Fry D; Delaney SN; Wei SC; Zhang J; Maitra A; Yee C
Gastroenterology; 2020 Jul; 159(1):306-319.e12. PubMed ID: 32179091
[TBL] [Abstract][Full Text] [Related]
37. Inhibition of myeloid-derived suppressive cell function with all-trans retinoic acid enhanced anti-PD-L1 efficacy in cervical cancer.
Liang Y; Wang W; Zhu X; Yu M; Zhou C
Sci Rep; 2022 Jun; 12(1):9619. PubMed ID: 35688951
[TBL] [Abstract][Full Text] [Related]
38. Oncolytic herpes simplex virus HF10 (canerpaturev) promotes accumulation of CD8
Eissa IR; Mukoyama N; Abdelmoneim M; Naoe Y; Matsumura S; Bustos-Villalobos I; Ichinose T; Miyajima N; Morimoto D; Tanaka M; Fujimoto Y; Sone M; Kodera Y; Kasuya H
Int J Cancer; 2021 Jul; 149(1):214-227. PubMed ID: 33687756
[TBL] [Abstract][Full Text] [Related]
39. TIGIT and PD-1 Immune Checkpoint Pathways Are Associated With Patient Outcome and Anti-Tumor Immunity in Glioblastoma.
Raphael I; Kumar R; McCarl LH; Shoger K; Wang L; Sandlesh P; Sneiderman CT; Allen J; Zhai S; Campagna ML; Foster A; Bruno TC; Agnihotri S; Hu B; Castro BA; Lieberman FS; Broniscer A; Diaz AA; Amankulor NM; Rajasundaram D; Pollack IF; Kohanbash G
Front Immunol; 2021; 12():637146. PubMed ID: 34025646
[TBL] [Abstract][Full Text] [Related]
40. High baseline tumor burden-associated macrophages promote an immunosuppressive microenvironment and reduce the efficacy of immune checkpoint inhibitors through the IGFBP2-STAT3-PD-L1 pathway.
Wen Z; Sun H; Zhang Z; Zheng Y; Zheng S; Bin J; Liao Y; Shi M; Zhou R; Liao W
Cancer Commun (Lond); 2023 May; 43(5):562-581. PubMed ID: 37031362
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]